Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV2-hCHM for Choroideremia
NCT02341807Phase 2Completed
- Sponsor
- Spark Therapeutics
- Start
- Jan 2015
- Primary completion
- Oct 2022
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 2, open-label trial of SPK-7001 in choroideremia (3 cohorts), sponsored by Spark Therapeutics. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events up to 5 years. Started Jan 2015; status: completed.
02
Drugs
SPK-7001
03
Conditions
choroideremia
Beyond the preview
Go deeper on NCT02341807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02341807.